Alexander Denner

HyperMed, Inc. develops medical imaging devices. The firm provides its services to the vascular surgeons, vascular laboratories, foot and ankle surgeons, podiatrists, research organizations, and educational institutions. The company was founded in 1997 and is headquartered in Burlington, MA.

Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)

Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY.

VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA.

Sarissa Capital Management LP (Sarissa) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Greenwich, Connecticut. The firm was founded in 2012 by Alexander Denner and Mayuran Sriskandarajah. Sarissa provides investment advisory services to pooled investment vehicles operating as private investment funds.

ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA.

The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.

Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA.

Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos.

Sarissa Capital Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination with one or more businesses. The company was founded on August 12, 2020 and is headquartered in Greenwich, CT.

Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA.